6054-16-6

Usage

Uses

Used in Pharmaceutical Industry:
NSC45401 is used as an antineoplastic agent for its potential to induce apoptosis in cancer cells, offering a therapeutic approach for the treatment of certain types of cancer.
Used in HIV Treatment:
NSC45401 is used as an anti-HIV agent for its inhibitory effects on the HIV-1 integrase and reverse transcriptase enzymes, which are crucial for the replication of the virus, thereby providing a potential treatment strategy for HIV-infected individuals.
Used in Cancer Research:
NSC45401 is used as a research compound for further investigation into its antineoplastic properties and its potential as a therapeutic agent in the treatment of various types of cancer.
Used in HIV Research:
NSC45401 is used as a research compound to study its anti-HIV activity and to explore its potential as a therapeutic agent in the treatment of HIV infection, particularly in the development of new antiviral drugs.

InChI:InChI=1/C7H8O3/c8-6-4-1-2-5(3-4)7(9)10-6/h4-5H,1-3H2

Upstream product

• 876-05-1 cis-1,3-cyclopentanedicarboxylic acid 
• 498-66-8 norborn-2-ene 
• 826-02-8 cis-cyclopentane-1,3-dicarboxylic acid 
• 498-66-8 norbornene 
• 855753-59-2 cyclopentane-1,1,3,3-tetracarboxylic acid 

Downstream Products

• 82524-90-1 N,N'-diphenyl-cyclopentane-1,3-dicarboxamide 
• 5763-45-1 3-aza-bicyclo[3.2.1]octan-2,4-dione 
• 192824-56-9 3-benzyl-3-azabicyclo[3.2.1.0]octane-2,4-dione 
• 732251-89-7 C₁₃H₁₄O₃ 
• 1155271-92-3 C₁₃H₁₄O₃ 
• 1098881-13-0 (1R,3S)-3-(methoxycarbonyl)cyclopentane-1-carboxylic acid 
• 85174-63-6 (+/-)-methyl cis-3-(chloromethanoyl)cyclopentanecarboxylate 
• 78795-20-7 (+/-)-cis-3-aminocyclopentanemethanol 
• 78795-25-2 (+/-)-1--5-methyl-2,4(1H,3H)-pyrimidinedione 
• 116940-85-3 (+/-)-cis-3-(hydroxymethyl)cyclopentanecarboxamide 

Relevant academic research and scientific papers

TREK Channel Family Activator with a Well-Defined Structure-Activation Relationship for Pain and Neurogenic Inflammation

TWIK-related K+ (TREK) channels are potential analgesic targets. However, selective activators for TREK with both defined action mechanism and analgesic ability for chronic pain have been lacking. Here, we report (1S,3R)-3-((4-(6-methylbenzo[d]

Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists

2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[2-(phenylsulfanyl)ethyl]guanidine (UR-PI376, 1) is a potent and selective agonist of the human histamine H4 receptor (hH4R). To gain information on the active conformation, we synthesized analogues of 1 with a cyclopentane-1,3-diyl linker. Affinities and functional activities were determined at recombinant hHxR (x: 1-4) subtypes on Sf9 cell membranes (radioligand binding, [35S]GTPγS, or GTPase assays) and in part in luciferase assays on human or mouse H4R (HEK-293 cells). The most potent H4R agonists among 14 racemates were separated by chiral HPLC, yielding eight enantiomerically pure compounds. Configurations were assigned based on X-ray structures of intermediates and a stereocontrolled synthetic pathway. (+)-2-Cyano-1-{[trans-(1S,3S)-3-(1H-imidazol-4-yl)cyclopentyl]methyl}-3-[2-(phenylsulfanyl)ethyl]guanidine ((1S,3S)-UR-RG98, 39a) was the most potent H4R agonist in this series (EC50 11 nM; H4R vs H3R, >100-fold selectivity; H1R, H2R, negligible activities), whereas the optical antipode proved to be an H4R antagonist ([35S]GTPγS assay). MD simulations confirmed differential stabilization of the active and inactive H4R state by the enantiomers.

BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

Highly enantioselective desymmetrizations of meso-anhydrides

Readily available, low molecular cyclohexane-based organocatalysts promote highly enantioselective desymmetrizations of cyclic meso-anhydrides applying alcohols and benzyl mercaptan as nucleophiles. Both succinic and glutaric anhydrides furnished the corresponding products with up to 96% ee in mostly quantitative yields.

Synthesis and antiviral activities of some novel carbocyclic nucleosides

cis-3-Aminomethylcyclopentylmethanol (4), prepared from norbornene (5) in four steps and 51% overall yield, was used as a precursor in the synthesis of carbocylic nucleosides 13 - 18 containing guanine and 8-azaguanine bases. None of these compounds had a

Chemoenzymatic Enantioselective Synthesis of Amidinomycin

We report the first asymmetric synthesis of amidinomycin, an antiviral antibiotic metabolite.Amidinomycin of high enantiomeric purity (ee 91percent) was prepared from norbornylene in 8 steps.The key step is an enzymatic discrimination of enantiotopic groups in meso cis-1,3-dicarbomethoxycyclopentane or in meso cis-cyclopentane-1,3-dicarboxylic acid anhydride.

Bridged bicyclic imides as anxiolytics and antidepressants

A series of bridged bicyclic imide compounds having a 4-(4-[2-pyrimidinyl]-1-piperazinyl)butyl group attached to the imide nitrogen are useful for alleviating the symptoms of anxiety and depression in human subjects.

Enantioselective synthesis of (+) and (-)-cis-3-aminocyclopentanecarboxylic acids by enzymatic asymmetrization

Both enantiomers of cis-3-aminocyclopentanecarboxylic acid (GABA analogs, inhibitory neurotransmitter) have been prepared via enzymatic asymmetrization of cis -1,3-cyclopentanedicarboxylic acid.

Bridged bicyclic imides as anxiolytics and antidepressants

A series of bridged bicyclic imide compounds having a 4-(4-[2-pyrimidinyl]-1-piperazinyl)butyl group attached to the imide nitrogen are useful for alleviating the symptoms of anxiety and depression in human subjects.